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Abstract
To date, microarray analyses have led to the discovery of numerous individual ‘molecular signatures’ associated with 
specific cancers. However, there are serious limitations for the adoption of these multi-gene signatures in the clinical 
environment for diagnostic or prognostic testing as studies with more power need to be carried out. This may involve larger 
richer cohorts and more advanced analyses. In this study, we conduct analyses—based on gene regulatory network—to 
reveal distinct and common biomarkers across cancer types. Using microarray data of triple-negative and medullary breast, 
ovarian and lung cancers applied to a combination of glasso and Bayesian networks (BNs), we derived a unique network-
containing genes that are uniquely involved: small proline-rich protein 1A (SPRR1A), follistatin like 1 (FSTL1), collagen type 
XII alpha 1 (COL12A1) and RAD51 associated protein 1 (RAD51AP1). RAD51AP1 and FSTL1 are significantly overexpressed 
in ovarian cancer patients but only RAD51AP1 is upregulated in lung cancer patients compared with healthy controls. The 
upregulation of RAD51AP1 was mirrored in the bloods of both ovarian and lung cancer patients, and Kaplan–Meier (KM) 
plots predicted poorer overall survival (OS) in patients with high expression of RAD51AP1. Suppression of RAD51AP1 by 
RNA interference reduced cell proliferation in vitro in ovarian (SKOV3) and lung (A549) cancer cells. This effect appears to be 
modulated by a decrease in the expression of mTOR-related genes and pro-metastatic candidate genes. Our data describe 
how an initial in silico approach can generate novel biomarkers that could potentially support current clinical practice and 
improve long-term outcomes.
Introduction
Microarray analyses of cancer patients over the years have led 
to the discovery of specific ‘molecular signatures’, but there 
are limitation in their adoption for diagnostic or prognostic 
purposes. For example, data available from next generation 
sequencing and RNAseq have provided a plethora of informa-
tion regarding differential expression of genes or mutations, but 
most of this data requires further validation. In addition, most 
studies concentrate on tissues, which are not readily accessible 
for use as biomarkers as liquid biopsies.
To make matters more complicated, a recent study revealed 
extensive genetic similarities across 14 major cancer types 
(breast, lung and ovarian amongst them) based on whole exome 
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somatic mutation profiles (1). This has been corroborated by 
studies demonstrating similarities between carcinomas from 
different organs, such as high-grade serous ovarian carcinomas, 
basal-like breast cancer and uterine serous carcinomas (2–4).
Thus, generic analyses may reveal distinct and common gen-
etic features across cancer types, and if so, these features could 
have the potential to be biomarkers of diagnostic or prognostic 
value. For this reason, we have employed the Unique Network 
Identification Pipeline (UNIP) focusing on four different cancer 
datasets: ovarian cancer, lung cancer, triple-negative breast 
and medullary breast cancer. UNIP aims to semi-automatically 
identify an enriched set of genes and the relationships between 
them, specific to one or a number of independent studies (5).
This is of particular importance to ovarian cancer, since it 
has been shown to be ineffective and possibly harmful for some 
(UK Collaborative Trial of Ovarian Cancer Screening) (6). Ovarian 
cancer is known as the ‘silent killer’ as it causes no symptoms 
in the early stages which makes detection problematic. Even in 
advanced disease, the symptoms are very vague. Current strate-
gies to diagnose ovarian cancer and recurrent ovarian cancer in 
patients with symptoms are based on blood tests and imaging. 
The most common screening tools used are measurement of 
the serum cancer antigen 125 and transvaginal ultrasound (7). 
Unfortunately, cancer antigen 125 does not have the required 
specificity and sensitivity for routine screening; in a study that 
randomized approximately 40 000 women, at no special risk for 
ovarian cancer, Buys et al. (7) found no statistically significant 
reduction in mortality from ovarian cancer in the screened (six 
annual cancer antigen 125 tests and four annual transvaginal 
ultrasounds) cohort of women versus those randomized to no 
screening intervention (7). Therefore, there is a need for the dis-
covery of more specific and sensitive biomarkers. In this study, 
we have identified, through NCBI (8), a list of genes known to 
be involved uniquely in each type of cancer. From all the iden-
tified candidate genes, assessment of the function, expression 
and signalling characteristics of a potential novel biomarker 
termed RAD51AP1 was chosen, as this gene, common to all four 
cancers, is known to be overexpressed in both lung and ovarian 
cancer patients in both tissue and blood compared with healthy 
controls.
Methodology
UNIP description
GSE18864 (triple-negative breast), GSE9891 (ovarian), GSE21653 
(medullary breast) and GSE10445 (non-small cell adenocar-
cinoma of lung) cancer datasets are downloaded from NCBI 
Gene Expression Omnibus database. Robust multi-array average 
expression measure was applied as a pre-processing step (9–11). 
To enrich the genes required for the analysis, the R function 
pvacFilter is applied separately for each study (breast, ovarian, 
medullary and lung; https://www.rdocumentation.org/pack-
ages/pvac/versions/1.20.0/topics/pvacFilter). This filter function 
involves two main steps. First, it performs principal component 
analysis for each individual probe set, and the proportion of 
variation explained by the first component PC1 (PVAC) is used to 
measure the degree of consistency among probes within a probe 
set. Second, it derives an empirical distribution of the PVAC 
scores of the probe sets that are called ‘Absent’ and sets the 99% 
percentile value of this distribution (with a maximum value of 
0.5, i.e. 50% of the total variation) as the threshold and applies it 
to all the probe sets on the chip (i.e. filtering out probe sets with 
PVAC scores less than the threshold value; https://www.biocon-
ductor.org/packages/devel/bioc/vignettes/pvac/inst/doc/pvac.
pdf, https://www.ncbi.nlm.nih.gov/pubmed/21525126). pvac 
Filter includes variables that account for most of the variation in 
the data and filters out genes with little variation. PVAC scores 
are provided as Supplementary Tables 1 and 2, available at 
Carcinogenesis Online.
Across all the samples for each of the cancer types (high-
grade serous ovarian, non-small cell lung, medullary and triple-
negative breast cancers), the standard deviation (SD) of each 
gene profile is calculated and only genes with SD > 1.5 (threshold 
decided based on the number of genes believed to be reason-
ably analysed) in at least one of the four studies are selected. To 
build a gene regulatory network for each condition/study in the 
dataset, we applied glasso (9,11), which calculated the inverse 
covariance matrix using the lasso penalty to enforce sparseness, 
with the penalization parameter rho = 0.05. To further improve 
the sparsity and reduce the nodes involved, we only maintained 
the connections with an inverse covariance value ≥0.8. The 
thresholds were set in order to balance filtering out an appropri-
ate amount of uninformative signal while not removing impor-
tant information that may be key in the identification of unique 
pathways. Given the poor diagnostic/prognostic landscape, we 
focussed on the ovarian cancer structure. For the ovarian cancer 
subtype, connections that do not appear in any other study net-
work are isolated. Genes involved in these unique connections 
are selected, and the Bayesian network (BN) (12) is applied to 
infer the unique network for the ovarian cancer dataset.
Sample collection and preparation
Tissue cDNA Array plates were purchased from Origene™ 
(Rockville, MD, USA), consisting of three cancer subtypes: lung, 
ovarian and breast, with five individual patient samples per 
cancer type, including one normal control.
Tissue and blood samples were collected from lung and 
ovarian cancer patients and non-malignant normal organ tis-
sue from consenting patients undergoing tissue biopsies/sur-
gical resections. Lung cancer tissue was collected from Harefield 
Hospital, London. Ovarian cancer samples were obtained from 
the University of Thessaloniki, Greece (13) and Mount Vernon 
Cancer Centre, London.
All samples were retrieved in formalin fixed, paraffin embed-
ded blocks. Tissue sections were cut at 5 µm using a microtome, 
followed by oil immersion to remove paraffin. Forty milligrams 
of ovarian/lung tissue were lysed in a Qiagen Tissue Lyser II for 
2 min with a 3 mm stainless steel ball bearing.
Cell lines
Two cell lines were used as in vitro models for lung (A549; ATCC, 
USA) and ovarian (SKOV3; ATCC, USA) cancer. Both cell lines have 
been authenticated by providing SKOV3 cells to DNA Diagnostics 
Abbreviations 
BNs  Bayesian networks
COL12A1  collagen type XII alpha 1
FBS  foetal bovine serum
FSTL1  follistatin like 1
KM  Kaplan Meier
OS  overall survival
PBS  phosphate buffered saline
RAD51AP1  RAD51 associated protein 1
SPRR1A  small proline-rich protein 1A
TBS  tris-buffered saline
UNIP  unique network identification pipeline
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Centre (4 August 2016) and by providing DNA from A549 cells to 
NorthGene (20 April 2017). Cells were grown in Dulbeccos modi-
fied Eagle medium (PAA), supplemented with 10% foetal bovine 
serum (FBS) (Gibco), and 1% penicillin/streptomycin (Gibco), or 
Roswell Park Memorial Institute media supplemented with 10% 
FBS (Gibco) and 1% penicillin/streptomycin (Gibco), respectively. 
Cell lines were cultured at 37°C, 5% CO2 in a humidified environ-
ment. Once cells reached 70% confluency, they were harvested 
and RNA extracted.
RNA isolation, cDNA synthesis and 
quantitative RT-PCR
RNA was extracted from cell lines and tissue samples, using 
the GenElute mRNA MiniPrep Kit (Sigma-Aldrich), a silica 
membrane/spin column method, and stored at −80°C until 
further use.
RNA from the lung tissue sections was extracted using the 
Promega formalin fixed, paraffin embedded RNA extraction 
kit (Promega) and stored at −80°C until further use. cDNA was 
synthesized from mRNA using Superscript II (Invitrogen). cDNA 
concentration was normalized using RNA concentrations deter-
mined by NanoDrop (Thermo Scientific) and was synthesized 
to a concentration of 1000  ng. RNA from blood samples was 
extracted using the Ribopure blood RNA kit (Ambion, Fisher, UK) 
according to the manufacturer’s protocol.
RT-qPCR of tissue samples
Relative expression of the genes of interest was assessed by 
quantitative PCR using the SYBR green PCR mastermix ROX 
(ABI, UK). β-Actin was used as the endogenous control for all 
samples, as recommended by the manufacturers of the Tissue 
Array plates, and to maintain consistency across the rest of 
the samples. GAPDH was also used for all clinical samples, and 
for cell line qPCR, B2M and YHWZA were used as endogenous 
controls based on GeNorm analyses. The following primers were 
used from PrimerDesign (Chandlers Ford, UK), RAD51 associ-
ated protein 1 (RAD51AP1 F: AGTGAAGGTAAAATCCCCAGTAGA, 
R: TGGCAAGGACTGAGATTCTGAT), collagen type XII alpha 1 
(COL12A1 F: GTGCCTGGACTGATTTGGTTT; R: AGACACAAGAG 
CAGCAATGAAG), follistatin like 1 (FSTL1 F: TAAAGGCAG 
CAACTACGTGAAAT; R: TTGTTCTCCTGGTCTGGATACG) and 
small proline-rich protein 1A (SPRR1A F: GCCACTGGATA 
CTGAACACC, R: AGAATGAGGGTAAGGGACATC TT). qPCR data 
of relative gene expression was analysed using the ΔCt method 
whereby the endogenous control Ct is subtracted from the 
gene of interest Ct to calculate ΔCt, and an relative quantity 
value was calculated by finding 2−ΔCt. Where more than one 
reference gene was used, the relative quantity values were 
averaged. A  Student’s unpaired t-test was used to calculate 
statistical significance.
Immunofluorescence microscopy
Seventy thousand cells were seeded onto coverslips in indi-
vidual wells of a 24-well plate. Cells were left to adhere for up 
to 24 h and then fixed with 4% paraformaldehyde and permea-
bilized with 0.5% Triton X-100. Coverslips were then blocked in 
5% FBS/phosphate buffered saline (PBS) (vol/vol) and incubated 
with rabbit anti-human RAD51AP1 antibody (Bioscience) at a 
dilution of 1:100 in 5% FBS/Tris-buffered saline (TBS) (vol/vol). 
Coverslips were washed with 5% FBS/PBS (vol/vol) before being 
incubated with a staining solution that consisted of Alexafluor 
488 secondary anti-rabbit antibody at a dilution of 1:1000 in 5% 
FBS/PBS (vol/vol), (Invitrogen, Life Technologies), for 45 min in 
the dark. After washing with 5% FBS/PBS, the coverslips were 
mounted onto slides and visualized on a HF14 Leica DM4000 
microscope.
ImageStreamx Mark II flow cytometry
A confluent 75 cm2 flask of SKOV3 and A549 cells, respectively, 
was split evenly into eppendorf tubes, which were centrifuged at 
1500 rpm for 5 min. The supernatant was discarded and the pel-
let was washed with sterile PBS, followed by another spin for 3 
min at 2000 rpm. Cells were fixed in 4% paraformaldehyde for 7 
min on ice and then centrifuged for 5 min at 1500 rpm. The pellet 
was washed with PBS and spun at 2000 rpm for 3 min. Cells were 
blocked for 30 min in FBS-PBS and then centrifuged at 2000 rpm for 
3 min. The pellet was incubated overnight with primary antibody 
(RAD51AP1) diluted in FBS-PBS (1:200) at 4oC. After incubation, cells 
were centrifuged at 2000 rpm for 3 min and then washed with 
PBS. Secondary horseradish peroxidase (HRP)-conjugated anti-
rabbit antibody diluted in FBS-PBS (1:200) was added to the cells 
for a 30 min incubation. The cells were centrifuged and washed 
once more as described above. Accumax (Sigma) and the nuclear 
marker DRAQ5 (BioStatus) were added before visualizing in the 
ImageStream. Compensation samples, that only contained anti-
bodies or only DRAQ5, were used for data normalisation. Data and 
images were analysed using an ImageStreamx Mark II Imaging 
Flow Cytometer (Amnis, Merck Millipore).
RAD51AP1 knockdown
We used siRNA targeted to RAD51AP1 (SMARTpool: 
ON-TARGETplus, Dharmacon, CO, USA) to suppress RAD51AP1 
expression in SKOV-3 and A549 cells. Both cell lines were 
seeded at 2 × 104 and 1 × 105 cells, per well in 6-well and 24-well 
plates, respectively. Transfection efficiency was determined 
previously with siGLO-labelled siRNA to be more than 90%. 
The siRNA transfection was carried out once at a concentra-
tion of 50  nmol/L per well/dish using Dharmafect 1 transfec-
tion reagent and serum-free media, a scrambled control was 
also included (ON-TARGETplus Non-targeting Pool; Thermo 
Scientific). Complete medium was added to the transfection mix 
to ensure that transfections (one hit) were carried out in serum-
containing medium. Twenty-four hours after transfection, the 
medium in the wells were replaced with fresh complete media, 
to avoid toxicity. RNA and lysate cell samples were collected at 
baseline, 48 and 72 h post transfection.
Western blotting
Protein lysates were extracted from transfected and control 
SKOV3 and A549 cells. Proteins were first separated by a 10% v/v 
SDS-PAGE. The separated proteins were then electrophoretically 
transferred onto a nitrocellulose membrane (Thermo Scientific, 
Massachusetts, USA) in wet transfer buffer as described previ-
ously (13). The membrane was incubated in Tris-buffered saline 
containing 5% dried milk powder (wt/vol) and 0.1% Tween-
20, for 1 h at room temperature to block non-specific binding. 
The membrane was then incubated with primary anti-human 
RAD51AP1 polyclonal antibodies (raised in rabbit), at 4oC over-
night. The membranes were washed in Tris-buffered saline + 
0.1% Tween-20 (three times, 15 min each) before incubation with 
the secondary anti-rabbit HRP-conjugated secondary antibody 
for 1 h at room temperature.
Microarrays and analysis
Experiments were performed in pooled biological replicates. 
The extracted RNA was quality verified on a 2100 expert Agilent 
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bioanalyzer, all samples had an RNA yield greater than 30 μg and 
RNA integrity number values of 10 (Supplementary Figure 1A, 
available at Carcinogenesis Online). Samples were amplified and 
labelled with Agilent Low Input Quick Amp labelling two colour 
kit and hybridized with a dye swap to an Agilent G3 8plex × 60k 
gene Human transcriptome microarray and washed to supplier’s 
protocol. The array slide was scanned at 3 μM and 20 bit tagged 
image file format (TIFF) file dynamic range on an Agilent Surescan 
G2565CA microarray scanner at 100% photomultiplier tube gain 
for both red and green lasers and exported TIFF images. The TIFF 
images were then aligned to their design files, quality controlled 
and converted into probe intensity values using the Agilent 
Feature Extraction Software Ver 12.0.1.1. Using this software, this 
data was probe and Loess normalized and then quantile normal-
ized for subarray variation using Genespring 14.8 GX – Build 7274 
(Agilent) and baseline transformed by the median of all samples. 
Genes showing 2-fold change between groups and moderated 
t-test significance P-value < 0.05 to remove technical variation (no 
false discovery rate was carried out due to small sample num-
bers) were enriched and loaded into pthways analysis module 
of Genespring and compared with Wikipathways January 2017 
release, BioCyc Ver 20.5 and KEGG Release 81.0 annotated path-
ways to report on significantly enriched pathways (14–16).
Results
Unique networks predicted four unique genes for 
ovarian and lung cancer
Application of the previously developed UNIP (5) was used to 
analyse four different cancer datasets: triple-negative and 
medullary breast, ovarian and lung cancers. Initially, enrich-
ment of the interesting genes was undertaken using principal 
Figure 1. Unique network for ovarian cancer. Grey nodes indicate highly predictive (average correct-prediction level higher or equal to 0.6) genes.
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component analysis and a threshold on the standard deviation. 
Glasso was then applied to identify a gene regulatory network 
for each cancer subtype and derive unique connections com-
mon to the networks. BN was applied to obtain the unique net-
work structure (Figure 1) for each cancer subtype and identify, 
through inference, the most predictive (how well it predicts 
other expression level values) and predictable (how well its 
expression level values are predicted) genes within (intra) and 
outside (inter) the cancer subtypes using the leave-one-out 
cross-validation technique. In Figure  1, the nodes with a grey 
background indicate genes with intra-study predicted accuracy 
higher than 0.6.
To capture study-specific genes, we queried GeneCards 
encyclopaedia to obtain the list of genes that are known to be 
involved in each cancer. We compared the list for each study 
to the others and to the list of genes included in the unique 
networks and, finally, selected the genes that appeared in the 
ovarian cancer study as described in methods. This pipeline 
identified four novel markers: SPRR1A, FSTL1, COL12A1 and 
RAD51AP1.
RAD51AP1 is overexpressed in tissue and blood of 
ovarian and lung cancer patients
The in silico observations were expanded, by assessing the rela-
tive expression of the four genes common to the four cancer 
subtypes (ovarian, lung and triple-negative and medullary 
breast cancers). ‘RAD51AP1’, ‘COL12A1’ and ‘SPRR1A’ were sig-
nificantly overexpressed in lung when compared with ovarian 
cancer, and ‘FSTL1’ was significantly overexpressed in ovarian 
cancer compared with lung and breast cancer (Figure 2).
The expression of these four identified genes was compared 
with healthy controls for lung and ovarian cancer patients. There 
was no comparison to a cohort of healthy breast tissue due to 
ethical restrictions. Using clinical samples, we demonstrated 
that ‘RAD51AP1’ and ‘FSTL1’ are significantly overexpressed in 
ovarian cancer patients compared with healthy control tissue 
(Figure 3A and B), whereas there was no apparent significance in 
expression of ‘COL12A1’ and ‘SPRR1A’ (Figure 3C and D).
When the same genes were assessed in our lung cancer 
cohort, there were no major changes in the gene expression for 
any of them when compared with healthy controls (Figure 3E-H). 
A significant upregulation in the expression was noted in total 
RNA extracted from total blood of ovarian (n = 28) and lung cancer 
(n = 18) patients compared with healthy controls (n = 12 and 16, 
ovarian and lung normal samples respectively; Supplementary 
Figure 1B and C, available at Carcinogenesis Online).
Kaplan–Meier (KM) plots (17) predict poorer overall sur-
vival (OS) of ovarian cancer patients with overexpression of 
RAD51AP1, FSTL1 and COL12A1 but not SPRR1A (Figure 4A-D). 
Interestingly, when KM plots were applied to lung cancer 
patients, poorer OS was also predicted in patients who overex-
pressed RAD51AP1, and SPRR1A, and those with low expression 
of FSTL1, whereas COL12A1 was not predictive (Figure 4E-H).
siRNA of RAD51AP1 reduced cell proliferation 
in vitro
From the in silico and qPCR data generated from the clinical 
samples, it appears that RAD51AP1 is an important gene, which 
is implicated in both ovarian and lung cancers as a prognostic 
predictor. For this reason, RAD51AP1 was therefore chosen for 
further in vitro studies, using the SKOV3 and A549 cells lines as 
experimental models for ovarian and lung cancer, respectively. 
Using ImageStream and immunofluorescence analyses, it can 
be demonstrated that RAD51AP1 is aberrantly expressed as a 
protein in both cells lines (Figure  5A-D), rendering them suit-
able models for functional studies. Therefore, siRNA was used to 
silence RAD51AP1 in both cell lines.
A complete downregulation of RAD51AP1 at gene level and 
protein level was evident as early as 48 h post transfection for 
SKOV3 cells (Figure  5E and G). A  similar reduction in mRNA 
level was evident for A549 cells; however, further protein inhi-
bition was achieved at 72  h post transfection (Figure  5F and 
G). Silencing of RAD51AP1 resulted in significant inhibition of 
cell growth at 72  h for both cell lines compared with control 
untransfected and scrambled siRNA cells, whereas a modest 
but significant decrease in cell proliferation was also evident for 
SKOV3 at 48 h (Figure 5H and I).
Silencing RAD51AP1 downregulates pro-metastatic 
markers and the pro-survival mTOR signalling 
pathway
To gain a better insight into the inhibition of cell growth by 
siRNA, the expression of certain pro-metastatic markers and 
apoptotic genes, known to be involved in lung and ovarian 
Figure 2. Gene expression of SPRR1A, FSTL1, COL12A1 and RAD51AP1 in breast (Br), lung and ovarian cancer (OC) patients. *P < 0.05.
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cancer, was measured. Treatment of SKOV3 and A549 cells with 
siRNA for 72 h significantly reduced the pro-metastatic gene 
Sox2 compared with controls (Figure 6A). Transfection of siRNA 
did not exert an effect on the expression of SNAI1 in SKOV3 
cells, but SNAI1 expression was significantly reduced in A549 
cells (Figure 6B). Similarly, in SKOV3 cells, siRNA did not exert 
an effect on expression of the pro-apoptotic gene Fas at 72 h, 
whereas Fas expression in A549 cells after siRNA transfection 
was significantly reduced (Figure 6C), whereas the expression 
of another pro-apoptotic gene, Bax, was significantly decreased 
in both cell lines (Figure 6D). Collectively, these data suggest 
a cytostatic effect for RAD51AP1 rather a cytotoxic effect. 
This was further corroborated by studies where cleavage of 
caspase 3 remained unaltered following siRNA transfection 
(Supplementary Figure 1D and E, available at Carcinogenesis 
Online).
Finally, investigation of key genes in the mTOR signalling 
pathway was explored in vivo (SKOV3 and A549 cell lines). 
The expression of mTOR was significantly reduced in both 
SKOV3 and A549 cell lines in the siRNA samples (Figure  6E), 
whereas DEPTOR depicted cancer-specific expression, being 
upregulated in SKOV3 and downregulated in A549 compared 
with controls (Figure  6F). The expression of key components 
for mTORC1 and mTORC2, namely raptor and rictor, remained 
unaltered in SKOV3 but was markedly reduced in A549 cells 
(Figure 6G and H).
Figure 3. Expression of RAD51AP1 (panels A and E), FSTL1 (panels B and F), COL12A1 (panels C and G), SPRR1A (panels D and H) in ovarian (A-D) and lung (E-H) cancers 
compared with healthy controls. *P < 0.05, **P < 0.01 and ***P < 0.001.
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Microarray analysis
We performed a whole genome microarray analysis in SKOV3 
cells transfected with RAD51AP1 siRNA and compared them 
with scrambled controls. We have decided to concentrate the in 
vitro model of ovarian cancer, given that screening is ineffective 
for this disease, and we would like to gain a better insight into 
the signalling of this potential biomarker. Moreover, complete 
protein knock down was achieved at 72 h post transfection in 
SKOV3 but not in A549 cells.
Gene expression values, which had a P-value derived from 
the unpaired Student’s t-test of less than 0.05 compared with 
the control and with a 2-fold change compared with the con-
trol, all others were discounted as displaying no significance. 
Overall, silencing RAD51AP1 significantly upregulated 124 genes 
and downregulated 21 genes. Genes with the greatest levels of 
downregulation or upregulation included RAD51AP1, multiple 
EGF-like-domains 6, connective tissue growth factor and zinc 
finger homeobox 4. Among the top 10 genes with the highest 
Figure 4. KM plotter predicted poorer OS of ovarian cancer patients patients with high expression of RAD51AP1 (A), FSTL1 (B) and COL12A1 (C) but not SPRR1A (D). 
When KM plots were applied for lung cancer patients, poorer OS was predicted with high expression of RAD51AP1 (E), and SPRR1A (H), and with low expression of 
FSTL1 (F), whereas COL12A1 was not a predictor (G).
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levels of upregulation were interleukin 1β, endothelial lipase, 
tumor necrosis factor, forkhead box A2 and intercellular adhe-
sion molecule 1 (Table 1). Enrichment analysis using GeneSpring 
Software using KEGG, Reactome and Wikipathways produced 32 
pathways that have four more genes changed in them includ-
ing apoptotic signalling, MAPK signalling, Toll-like receptor and 
PI3K-Akt-mTOR signalling (Supplementary Figure 2, available at 
Carcinogenesis Online).
Discussion
In this study, we provide evidence of how genes derived from 
unique networks can be of importance as potential biomarkers 
or therapeutic targets. Using a combination of glasso network 
learning, graph theory and BN prediction, the Unique Network 
approach enables us to explore many possible mechanisms in 
existing data by focussing on those that appear specifically in 
a subset of conditions—here four different cancer types. This is 
in stark contrast to many data integration techniques that risk 
‘averaging’ over multiple datasets. It does this through a combi-
nation of glasso network learning, graph theory and BN predic-
tion. Only genes that are predictive in the subset of cancer types 
are preserved in the unique networks and this approach has 
enabled us to identify one key gene termed RAD51AP1.
RAD51AP1 has been shown to participate in the homologous 
recombination DNA damage response pathway, as an accessory 
protein to RAD51, known as the main mediator (18). Interaction of 
the RAD51AP1 with RAD51 greatly enhances its recombinase activ-
ity, stimulating the RAD51-mediated D-loop reaction (18). Over the 
past years, novel roles for RAD51AP1 have emerged, including act-
ing as a growth promoting signalling molecule (19) and is possibly 
critical during early stages of neoplasia where replication stress 
occurs at higher than normal levels. Elevated levels of RAD51AP1 
can then shift the balance from a pre-cancerous lesion to cancer 
(20). In the same study, RAD51AP1-deficient cells appear to be sen-
sitized to cisplatin’s cytotoxic effects. Here, RAD51AP1 upregulation 
is described in both tissue and matching blood from patients with 
ovarian and lung cancer compared with healthy controls. These 
data expand and compliment previous cancer studies, where 
overexpression of RAD51AP1 has been described in cholangio-
carcinoma tissues (21), hepatocellular carcinomas (22) and acute 
myeloid leukaemia with complex karyotipic abnormalities (23). 
Moreover, data from publicly available microarrays corroborate 
our findings, demonstrating significant upregulation of the gene 
in ovarian and lung malignancies (Supplementary Figure 3, avail-
able at Carcinogenesis Online). The overexpression of RAD51AP1 
described above is associated with reduced OS in ovarian and lung 
cancer patients and this too is reported for breast cancer (19).
With the emergence of circulating tumour cells, readily avail-
able in the blood of lung and ovary cancer patients (24), there 
is renewed hope of developing this tool further to identify cir-
culating surrogate biomarkers, i.e. ‘liquid biopsy’ which would 
be considerably more accessible than repeated tissue biopsies. 
Circulating tumour cells are cells that have detached from the 
primary tumour, or a metastatic site, and entered the blood cir-
culation (25). Despite the limitations of biological heterogene-
ity and difficult identification of circulating tumour cells, there 
is an increasing evidence of the clinical utility of these and 
circulating free DNA as diagnostic, prognostic and predictive 
testing in cancer patients (26–28). Given the overexpression of 
RAD51AP1 in ovary and lung cancer patients tissue and periph-
eral blood, compared with normal healthy controls described 
here, RAD51AP1 could be explored as potential biomarker for 
both ovarian and lung cancer.
Figure 5. RAD51AP1 was aberrantly expressed—primarily in the nucleus—in both SKOV3 (A, B) and A549 cells (C, D), as it was evident by ImageStream (A, C) and im-
munofluorescent analyses (B, D). Using siRNA for RAD51AP1, a substantial and significant downregulation of the gene was evident at both 48 and 72 h post transfec-
tion for both SKOV3 (E) and A549 (F) cells compared with scrambled control. The downregulation was mirrored at protein level with maximal downregulation at 72 h 
post transfection (G). Silencing of RAD51AP1 resulted in significant inhibition of cell growth at 48 and 72 h for SKOV3 cells compared with control untransfected and 
scrambled siRNA cells (H), whereas in A549 cells a significant decrease in cell proliferation was also evident only at 72 h (I). **P < 0.01, ***P < 0.001. Magnification ×40.
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Using the cancer genome atlas microarray data, Miles et al., 
identified novel microRNA/mRNA mechanisms in ovarian can-
cer, demonstrating that the expression of RAD51AP1 is strongly 
inversely correlated with expression of hsa-miR-140-3p, which 
was significantly downregulated in the ovarian cancer samples. 
This downregulation was not seen in normal ovarian tissue 
samples, suggesting a direct causal dysregulation of RAD51AP1 
by hsa-miR-140-3p microRNA in the ovary, and this may play a 
part in tumorigenesis (29).
To investigate the role of RAD51AP1 in tumorigenesis, we 
have generated ovarian and lung cell lines silencing the gene 
using siRNA. We demonstrate for first time that suppressing 
RAD51AP1 in SKOV3 and A549 cells leads to a significant decrease 
in cell proliferation at 72 h post transfection. In a study using 
intrahepatic cholangiocarcinoma cells, RAD51AP1 suppression 
produced similar results (21).
This marked reduction in cell proliferation could be due 
to reduced expression of pro-metastatic genes. Following 
RAD51AP1 siRNA transfection into SKOV3 and A549 cells, SOX2 
was significantly downregulated. SOX2 (sex-determining region 
Y-Box2) is a transcription factor belonging to the SOX family. 
SOX2 is involved in embryonic development and regulating stem 
cell fate, as well as conferring and maintaining stem cell iden-
tities (self-renewal, an important hallmark of cancer-initiating 
Figure 6. Treatment of SKOV3 and A549 cells with siRNA for RAD51AP1 for 72 h reduced significantly the pro-metastatic gene Sox2 compared with scrambled/non-
targeting siRNA controls (A), whereas siRNA did not alter the gene expression of SNAI1 in SKOV3 cells but was significantly reduced in A549 cells (B). Similarly, Fas was 
only downregulated in A549 but not SKOV3 cells following siRNA transfection (C). On the contrary, expression of Bax (D) and mTOR (E) was significantly decreased in 
both cell lines. DEPTOR was upregulated in SKOV3 and downregulated in A549 compared with untransfected controls (F), whereas the expression raptor and rictor 
remained unaltered in SKOV3 but downregulated in A549 cells (G-H). *P < 0.05, **P < 0.01, ***P <0.001.
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cells). SOX2 has also been linked to epithelial mesenchymal 
transition, and studies show that knocking down SOX2 results 
in the decreased expression of drivers of epithelial mesenchy-
mal transition, including SNAI1 (30). Interestingly, SOX2 over-
expression occurs in the majority of patients with high-grade 
serous ovarian cancer irrespective of tumour stage (Hellner 
et al., 2016). However, a more cell-specific effect was noted for 
SNAI1, since transfection of RAD51AP1 siRNA did not alter its 
expression in SKOV3 cells but was significantly downregulated 
in A549 cells. SNAI1 is a transcription factor, shown to down-
regulate E-cadherin expression, resulting in loss of cell-to-cell 
adhesion and facilitating the epithelial mesenchymal transition, 
promoting metastasis (31).
With regards to Bax, this is not the first time that a variable 
expression is documented. For example, when FSTL1 gene was 
silenced in ovarian cancer cells, a decrease in proliferation was 
noted while the Bax gene expression remained unchanged (32). 
It is possible therefore, the mitochondrial-initiated intrinsic 
pathway of apoptotic events might not be involved, but the 
decrease in cell proliferation is due to a compromized mTOR 
signalling.
The mTOR signalling regulates growth, proliferation, con-
trols cellular behaviour and acts as a nutrient and amino acid 
sensor (33–36). Studies from our laboratory have shown involve-
ment of this pathway in drug resistance in ovarian cancer, medi-
ation of responses of the complement protein C1q (37) and as 
a therapeutic target, given that rapalogues can exert an inhibi-
tory effect on ovarian cancer cells (13). Here, we demonstrate 
that mTOR (the key component for both mTORC1 and mTORC2 
complexes) is significantly downregulated in both cell lines. For 
the remaining of the mTOR pathway genes, there is cell specific-
ity. For example, DEPTOR appeared to be upregulated in SKOV3, 
whereas the key components for mTORC1 and mTORC2, namely 
raptor and rictor, respectively, were downregulated only in A549 
cells but not in SKOV3 cells. Collectively, these data points 
towards a compromized mTOR signalling in both cell lines in 
vitro. In SKOV3 cells, decreased mTOR signalling along with the 
increase in DEPTOR would inhibit the activity of complexes, if 
protein mirrors the changes in the gene expression changes. In 
A549 cells, similarly compromized activity occurs through the 
reduction in expression of the key components (raptor and ric-
tor) of mTORC1 and mTORC2 complexes. Future work on protein 
expression of these components or changes in the phosphoryla-
tion status of downstream components, like S6 kinase, would 
provide a more detailed insight into the effects of RAD51AP1 on 
mTOR signalling.
To summarize, unique networks and unique genes are 
derived in a way that only the genes that are uniquely involved 
in the mechanism considered and not in any other are selected. 
This means that unique networks of different conditions can 
still include genes that are present in both as long as they are 
connected in different ways. The main risk of unique networks 
is small sample sizes may affect the significance of the connec-
tions identified. This is increased the more specific the networks 
become, the opposite to data integration. However, prediction 
experiments demonstrate the power of the learnt network mod-
els (avoiding overfitting). Also, although BNs are excellent at 
dealing with uncertainty and noisy data, they do not scale well. 
This is to overcome a degree by using glasso approaches.
Finally, RAD51AP1 is not only overexpressed in lung and 
ovarian cancer tissue but also readily identified in the peripheral 
blood of these patients as opposed to normal healthy controls. 
Thus, it has the potential to be biomarker. Future studies using 
‘liquid biopsies’will also provide evidence as to whether this 
gene can be of diagnostic value non-invasively. In addition, the 
knocking out RAD51AP1 reduces cell proliferation in vitro pos-
sibly offering itself as a therapeutic target for ovarian and lung 
cancers. Preliminary work here suggests that RAD51AP1 has 
the potential to influence many pathways from pro-metastatic 
genes such as SOX2, transcription factors such as SNAI1 and the 
mTOR pathway.
Supplementary material
Supplementary data are available at Carcinogenesis online.
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